SCHEMBL26592018

SCHEMBL26592018

N#Cc1ccc(-c2ccc3cc(-c4nc(-c5ccc(-c6ccccc6)cc5)nc(-c5cc(-c6ccc(-c7cccc8ccccc78)cc6)ccc5-c5ccccc5)n4)ccc3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.43
CYP1A2 P05177 4/20 0.41
ALDH1A1 P00352 4/20 0.41
CYP2C19 P33261 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TSHR P16473 3/20 0.41
HSD17B10 Q99714 3/20 0.41
CYP2C9 P11712 2/20 0.41
CYP3A4 P08684 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
LMNA P02545 2/20 0.41
CYP2D6 P10635 1/20 0.41
ABCG2 Q9UNQ0 9/20 0.41
ABCB1 P08183 4/20 0.41
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26591990 0.95 CYP1A2 (0.43) CYP1A2ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL26591987 0.94 CYP1A2 (0.42) CYP1A2ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL26591977 0.93 ABCG2 (0.44) CYP1A2ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL25682321 0.92 CYP1A2 (0.45) PIM1CYP1A2ALDH1A1CYP2C19MEN1
SCHEMBL25682774 0.91 CYP17A1 (0.42) CYP1A2ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL26591992 0.91 ABCG2 (0.44) CYP1A2ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL26591989 0.91 ABCG2 (0.44) CYP1A2ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL25682314 0.91 ABCG2 (0.46) CYP1A2ALDH1A1CYP2C19MEN1KMT2A
SCHEMBL26592011 0.91 ABCG2 (0.48) ABCG2ABCB1CYP17A1CYP11B1CYP11B2
SCHEMBL26592005 0.90 CYP1A2 (0.50) CYP1A2ALDH1A1CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230337532-A1 TRIAZINE COMPOUND, MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, ELECTRON TRANSPORT MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, AND ORGANIC LIGHT EMITTING DIODE TOSOH CORPORATION (JP) 2023-10-19 US disclosed
US-20230337532-A1 TRIAZINE COMPOUND, MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, ELECTRON TRANSPORT MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, AND ORGANIC LIGHT EMITTING DIODE TOSOH CORPORATION (JP) 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230337532-A1 TRIAZINE COMPOUND, MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, ELECTRON TRANSPORT MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, AND ORGANIC LIGHT EMITTING DIODE ARNT, TPH1, AHR PIM1 3879/4885CYP1A2 15/4885ALDH1A1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.